Can carbimazole cause cholestasis?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18603561
Cited by: 0

Abstract

Carbimazole has been associated with cholestasis, a reversible condition characterized by impaired bile flow, during therapeutic use. Monitoring liver function is essential due to the potential for cholestatic hepatotoxicity.

Fields of Study & Subjects

Drug-Induced Hepatotoxicity and Protection Drug-Induced Adverse Reactions Pharmacovigilance and Adverse Drug Reactions

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
11 February 2026
Language
EN